ImmunoPrecise Antibodies Overview
- Year Founded
-
1989
- Status
-
Public
- Employees
-
101
- Stock Symbol
-
IPA
- Investments
-
8
- Share Price
-
$0.44
- (As of Wednesday Closing)
ImmunoPrecise Antibodies General Information
Description
ImmunoPrecise Antibodies Ltd is a techbio company that leverages multi-omics modeling and complex artificial intelligence through a series of proprietary and patented technologies. The Company owns an integrated end-to-end suite of capabilities to support the development of therapeutic antibodies and are known for solving very complex industry challenges. IPA has several subsidiaries in North America and Europe.
Contact Information
Website
www.ipatherapeutics.comCorporate Office
- 4837 Amber Valley Parkway
- Suite 11
- Fargo, ND 58104
- United States
Corporate Office
- 4837 Amber Valley Parkway
- Suite 11
- Fargo, ND 58104
- United States
ImmunoPrecise Antibodies Stock Performance
As of 23-Apr-2025, ImmunoPrecise Antibodies’s stock price is $0.44. Its current market cap is $20.3M with 45.8M shares.
(As of Wednesday Closing)
| Stock Price | Previous Close | 52 wk Range | Market Cap | Shares | Average Volume | EPS |
|---|---|---|---|---|---|---|
| $0.44 | $0.43 | $0.27 - $1.39 | $20.3M | 45.8M | 2.25M | -$1.22 |
ImmunoPrecise Antibodies Financials Summary
As of 31-Jan-2025, ImmunoPrecise Antibodies has a trailing 12-month revenue of $17.4M.
|
In Thousands, USD |
TTM 31-Jan-2025 | FY 2024 30-Apr-2024 | FY 2023 30-Apr-2023 | FY 2022 30-Apr-2022 |
|---|---|---|---|---|
| EV | 23,717 | 39,792 | 61,209 | 110,542 |
| Revenue | 17,389 | 18,152 | 15,522 | 15,427 |
| EBITDA | (32,684) | (16,990) | (15,893) | (9,778) |
| Net Income | (33,872) | (20,121) | (19,950) | (13,312) |
| Total Assets | 31,414 | 43,890 | 56,972 | 72,364 |
| Total Debt | 8,919 | 10,010 | 5,321 | 2,138 |
ImmunoPrecise Antibodies Valuation & Funding
| Deal Type | Date | Amount | Valuation/ EBITDA |
Post-Val | Status | Debt |
|---|
ImmunoPrecise Antibodies Comparisons
Industry
Financing
Details
ImmunoPrecise Antibodies Competitors (30)
One of ImmunoPrecise Antibodies’s 30 competitors is Immatics, a Formerly VC-backed company based in Tuebingen, Germany.
| Company Name | Financing Status | Location | Employees | Total Raised | Last Financing Date/Type | Last Financing Amount |
|---|---|---|---|---|---|---|
| Immatics | Formerly VC-backed | Tuebingen, Germany | ||||
| GenScript | Formerly VC-backed | Piscataway, NJ | ||||
| Affimed | Formerly VC-backed | Mannheim, Germany | ||||
| Coherus Biosciences | Formerly VC-backed | Redwood City, CA | ||||
| ProMab Biotechnologies | Corporate Backed or Acquired | Richmond, CA |
ImmunoPrecise Antibodies Related Research & Analysis
Explore institutional-grade private market research from our team of analysts.
-
Verticals
ImmunoPrecise Antibodies Patents
ImmunoPrecise Antibodies Recent Patent Activity
| Publication ID | Patent Title | Status | First Filing Date | Technology (CPC) | Citations |
|---|---|---|---|---|---|
| CA-2947722-A1 | Monoclonal antibodies for the identification and characterization of antiestrogens and selective estrogen receptor modulators | Inactive | 04-Nov-2016 | ||
| CA-2965017-A1 | Monoclonal antibodies for the identification and characterization of antiestrogens and selective estrogen receptor modulators | Inactive | 04-Nov-2016 | ||
| CA-2964907-A1 | Monoclonal antibodies and use thereof as a diagnostic tool for limb-girdle muscular dystrophy and genetically related disorders | Inactive | 04-Nov-2016 | ||
| CA-2947878-A1 | Monoclonal antibodies and use thereof as a diagnostic tool for limb-girdle muscular dystrophy | Inactive | 04-Nov-2016 | ||
| CA-2940065-A1 | Method for the rapid production of high affinity monoclonal anitibodies | Inactive | 22-Aug-2016 | C07K16/00 |
ImmunoPrecise Antibodies Signals
Growth Rate
Growth
Size Multiple
Key Data Points
Similarweb Unique Visitors
Majestic Referring Domains
ImmunoPrecise Antibodies Investors
| Investor Name | Investor Type | Holding | Investor Since | Participating Rounds | Contact Info |
|---|
ImmunoPrecise Antibodies Investments & Acquisitions (8)
ImmunoPrecise Antibodies’s most recent deal was a Corporate Asset Purchase with Carterra (LSA Instrument Platform). The deal was made on 20-Mar-2024.
| Company Name | Deal Date | Deal Type | Deal Size | Industry | Lead Partner |
|---|---|---|---|---|---|
| Carterra (LSA Instrument Platform) | 20-Mar-2024 | Corporate Asset Purchase | Buildings and Property | ||
| BioStrand (Other Healthcare Technology Systems) | 14-Apr-2022 | Merger/Acquisition | Other Healthcare Technology Systems | ||
| ModiQuest Research | 06-Apr-2018 | Merger/Acquisition | Discovery Tools (Healthcare) | ||
| CrossBeta Biosciences | 30-Jan-2018 | Merger/Acquisition | Biotechnology | ||
| SERPINx | 29-Dec-2017 | Corporate | Discovery Tools (Healthcare) |
ImmunoPrecise Antibodies Exits (1)
ImmunoPrecise Antibodies’s most recent exit was on 29-Dec-2017 from SERPINx. The exit was categorized as .
| Company Name | Exit Date | Exit Type | Exit Size | Status | Buyers |
|---|---|---|---|---|---|
| SERPINx | 29-Dec-2017 | Completed |
|
ImmunoPrecise Antibodies Affiliates
Subsidiaries (3)
| Name | Industry | Location | Year Founded |
|---|---|---|---|
| BioStrand (Other Healthcare Technology Systems) | Diepenbeek, Belgium | 2019 | |
| QVQ | Utrecht, Netherlands | 2009 | |
| CrossBeta Biosciences | Utrecht, Netherlands | 2005 |
ImmunoPrecise Antibodies FAQs
-
When was ImmunoPrecise Antibodies founded?
ImmunoPrecise Antibodies was founded in 1989.
-
Where is ImmunoPrecise Antibodies headquartered?
ImmunoPrecise Antibodies is headquartered in Fargo, ND.
-
What is the size of ImmunoPrecise Antibodies?
ImmunoPrecise Antibodies has 101 total employees.
-
What industry is ImmunoPrecise Antibodies in?
ImmunoPrecise Antibodies’s primary industry is Biotechnology.
-
Is ImmunoPrecise Antibodies a private or public company?
ImmunoPrecise Antibodies is a Public company.
-
What is ImmunoPrecise Antibodies’s stock symbol?
The ticker symbol for ImmunoPrecise Antibodies is IPA.
-
What is the current stock price of ImmunoPrecise Antibodies?
As of 23-Apr-2025 the stock price of ImmunoPrecise Antibodies is $0.44.
-
What is the current market cap of ImmunoPrecise Antibodies?
The current market capitalization of ImmunoPrecise Antibodies is $20.3M.
-
What is ImmunoPrecise Antibodies’s current revenue?
The trailing twelve month revenue for ImmunoPrecise Antibodies is $17.4M.
-
Who are ImmunoPrecise Antibodies’s competitors?
Immatics, GenScript, Affimed, Coherus Biosciences, and ProMab Biotechnologies are some of the 30 competitors of ImmunoPrecise Antibodies.
-
What is ImmunoPrecise Antibodies’s annual earnings per share (EPS)?
ImmunoPrecise Antibodies’s EPS for 12 months was -$1.22.
Data Transparency
-
Meet our data hygiene team
Discover how our experts ensure you’re getting the most accurate financial data in the industry.
Read blog » -
How PitchBook sources data
Our data operations team has logged over 3.5 million hours researching, organizing, and integrating the information you need most.
Discover our process »
